Qiagen to acquire U.K. firm that makes genetic tests

09/22/2009 | Forbes

German firm Qiagen said it agreed to acquire DxS, a U.K.-based maker of genetic tests, in an effort to broaden its cancer diagnostics business. The deal entitles DxS to receive $95 million in cash from Qiagen and up to $35 million in additional payments if certain milestones are met.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX